News and research before you hear about it on CNBC and others. Request your one week free trial to StreetInsider Premium Here.
George medication aPoint point Stefan Koenig as Chief Executive Officer
- Mr king joins in to lead Late stage drug development Corporate development proprietary Fixed dose combination therapies for non-communicable diseases
- US FDA grants IND approval for start Phase III studies with Triple Combination Candidate to treat high blood pressure
- Chief Business Officer, Karl Roberts, appointed to new role of Chief Operating Officer
London, United Kingdom, 3rd of June 2021 – George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, today announced the appointment of Stefan König as Chief Executive Officer.
George Medicines, a venture-backed spin-out from the George Institute for Global Health, one of the world’s leading independent medical research institutes, leverages its drug discovery and formulation expertise to create the best of existing treatments in fixed, ultra- low-dose combinations . These are designed to strike the optimum balance between high efficacy and improved safety, with the potential for significant improvements in clinical outcomes and long-term adherence to therapy. The company has received Investigational New Drug (FDA) approval from the U.S. Food and Drug Administration (FDA) to begin Phase III trials of its proprietary triple-combination candidate GMRx2 as a first-line treatment for high blood pressure.
Stefan joins George Medicines from Takeda Pharmaceuticals, most recently as Vice-President and Global Franchise Head, Inflammatory Bowel Disease (IBD). In his role, he was responsible for Takeda’s premier asset franchise, Entyvio (vedolizumab). Under Stefan’s leadership, the vedolizumab franchise grew into the gold standard therapy system for IBD patients with a significant life cycle plan for further, sustainable expansion. In this role, Stefan also oversaw the design of the global trading strategy and managed its implementation in regions and subsidiaries.
Prior to that, Stefan was General Manager of Takeda in Austria, where he led the integration of the major legacy organizations of Takeda and Nycomed and transformed the business from a primary care organization to an agile specialist in special care and oncology. Previous roles at Takeda were Regional Managing Directors for a group of countries in Central and Eastern Europe. Stefan also spent nearly 10 years in Mexico and Latin America, working in areas such as business and corporate development and marketing for various companies including Novartis and Merck.
Stefan holds a degree in business administration from the Ravensburg University of Cooperative Education, Germany, and an MBA from Georgia State University, Atlanta, USA.
Professor Stephen MacMahon, chairman by George Medicine, said: “I’m glad announce Stefan‘s appointment to George Medicines as our new Chief Executive Officer. George Medicines is Committed bring affordable, Easy to use, Life–Treatments change too Patient, so Stefan’s extensive Experience start New Products for common serious illnesses, along with his Knowledge of healthcare Systems global, will be of great value to the company. On behalf of the Executive Board and the management team, I would like to welcome Stefan to the company and look forward to working with him.
Stefan Koenig, Chief Executive Officer of George Medicines said: “I’m passionate about building enduring, sustainable businesses based on capable, very diverse, and talented teams working together to achieve something the best patient and Customer results. I am very excited to be with George Medicines, whose values include that approach. Now that we have received IND approval from the FDA to begin our Phase III studies with GMRx2, it will be a pivotal year for the company. I look forward to working with the team and reporting on our clinical progress in due course. “
The current Chief Business Officer of George Medicines, Dr. Karl Roberts, has also been appointed to a new role as the company’s Chief Operating Officer. Prior to joining George Medicines in 2018, Dr. Roberts Global Head of Business Development at Concordia and previously managed Cipla’s business in Western Europe, where he was instrumental in redesigning and implementing the company’s European growth strategy.
Karl Roberts, Chief Operating Officer
Strategic communication from Consilium
David Daley, Allison Connolly, Lindsey Neville
Tel: +44 (0) 203 709 5700
About George Medicines
George Medicines is a late-stage drug development company focused on improving NCD management with innovative combinations of existing drugs in a single pill, fixed dose.
George Medicines combines best-in-class molecules from existing drugs in fixed and low dose formulations to develop innovative and proprietary treatments that are more effective, safer and more affordable than currently available treatment options. These single, fixed-dose pill combinations have the potential to significantly improve clinical outcomes and therapy adherence in patients with cardiometabolic disorders such as heart disease, hypertension and diabetes, which remain the leading causes of premature death and disability worldwide.
George Medicines is building a strong and diversified pipeline of patented late-stage, single-pill, fixed-dose combination therapies. Its lead candidate for the first-line treatment of high blood pressure, GMRx2, has received approval for Phase III development from the US Food and Drug Administration (FDA).
George Medicines is a spin-out of the George Institute for Global Health, one of the world’s leading medical research institutes for non-communicable diseases. The company is supported by George Health, the commercial arm of the George Institute, and Brandon Capital Partners, Australia’s leading biomedical venture capital firm, backed by the Australian Government. For more information, please visit www.george-medicines.com